Press Releases

Press Releases

Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder (SAD). Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA consensus that data from nonclinical and clinical studies of
PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder FDA Fast Track designation granted Topline results anticipated mid-2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2022-- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS
SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Jun. 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other
VistaGen will present at upcoming William Blair 42 nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused
The FDA agreed that data from nonclinical and clinical studies of PH94B completed to date provide no signal of abuse potential The FDA also agreed that additional nonclinical studies are not necessary to evaluate the abuse potential of PH94B and, at this time, based on studies completed to date, a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and
Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology   highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled-PH94B is largely
Companies plan to initiate the global study of PH94B for the acute treatment of social anxiety disorder (SAD) in the second half of 2022 Trial designed to support commercialization of PH94B in China and other markets outside the U.S. SOUTH SAN FRANCISCO, Calif. & SHANGHAI --(BUSINESS WIRE)--Apr.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central
Displaying 1 - 10 of 194